Neuroimaging and Siemens Healthineers’ Push to Build a Neuro Platform

Siemens Healthineers sits among the largest companies in medtech. With approximately $25 billion in revenue in 2025, the company operates at a scale comparable to some of the industry’s biggest names and continues to invest heavily in markets where it sees long-term growth potential.

A series of partnership announcements over the past year offers a window into where Siemens Healthineers appears to be investing for the future. Across robotics, AI, diagnostics software, and health system infrastructure, Siemens Healthineers has assembled a network of relationships that increasingly points toward one destination: neuro. Viewed individually, each agreement serves a specific purpose. Taken together, they suggest a broader strategy centered on neuroimaging, precision therapy, and integrated clinical workflows.

A Company Becoming More Focused

Siemens AG announced plans to deconsolidate its majority stake in Siemens Healthineers, a process that has been underway for some time. For Healthineers, that focus appears increasingly concentrated on businesses where it believes it holds the strongest competitive advantages.

Imaging and Precision Therapy are viewed as the highly synergistic core of the company, and both segments are also posting high single-digit growth. Diagnostics occupies a different position. By management’s own admission, the business has relatively few synergies with either segment. While no formal separation has been announced, the discussion reflects a broader trend toward portfolio simplification across medtech.

The company’s own reporting reinforces this view. Imaging and Precision Therapy remain central to the growth story, while Diagnostics continues to face challenges, particularly in China.

The Partnerships Behind the Strategy

During the last 12 months, Siemens Healthineers announced nine notable partnerships spanning multiple areas of healthcare technology.

Three stand out as especially relevant to its broader neuro ambitions.

The partnership with Stryker, announced in September 2025, focuses on neurovascular workflows. The collaboration combines Siemens Healthineers’ imaging capabilities with Stryker’s therapeutic devices to support stroke and neurovascular interventions.

In May 2026, Siemens Healthineers partnered with Cercare Medical to integrate Cercare’s Neurosuite platform into syngo DynaCT. The combination enables automated cone-beam CT perfusion imaging within the angiography suite, with the goal of reducing the time between stroke diagnosis and treatment.

Another May 2026 announcement connected LSI Alumni company AiM Medical Robotics’ MRI-compatible robotic neurosurgery platform with Siemens Healthineers’ MAGNETOM MRI scanners. The collaboration enables real-time in-bore guidance during brain biopsies and neurostimulation procedures.

Building a Neuro Ecosystem

Additional agreements further strengthen the company’s position.

Methinks AI joined the ecosystem in October 2025, bringing AI-driven acute stroke triage capabilities. In February 2026, Siemens Healthineers and Mayo Clinic announced a collaboration focused on clinical digital twins and AI-enabled MRI/PET protocols for neurodegenerative disease and oncology applications.

The company has also signed health system partnerships with Northwestern Medicine, Onvida Health, and Hawaii Pacific Health. While less visible than robotics or AI announcements, these relationships help reinforce imaging infrastructure adoption across large provider networks.

Why Neuro?

The answer becomes clearer when looking at patient populations.

More than 800,000 Americans experience a stroke each year, while roughly 9 to 10 million people in the United States are living with a history of stroke.

The opportunity extends well beyond stroke alone:

• Approximately 7.2 million Americans aged 65 and older currently live with Alzheimer’s dementia, with projections showing that number nearly doubling by 2060.
• Nearly 100,000 new Parkinson’s disease diagnoses occur annually, and more than 1 million Americans are living with the condition.
• Roughly 3.4 million Americans have epilepsy.

Across each of these conditions, imaging plays a critical role in diagnosis, treatment planning, and ongoing monitoring.

This helps explain why Siemens Healthineers is investing in technologies such as AI-guided imaging, robotic neurosurgery, and advanced workflow solutions. These are large patient populations supported by long-term demographic trends, particularly aging populations that are expected to drive increasing demand for neuro care.

Recent activity across stroke and endovascular M&A demonstrates that Siemens Healthineers is not alone in identifying this opportunity. Stroke remains one of the most attractive growth markets in medtech, while neuro conditions more broadly continue to represent large and expanding addressable populations.

Technologies being developed by companies such as AiM Medical Robotics and Cercare Medical help advance Siemens Healthineers’ vision by connecting imaging, AI, and intervention more closely than traditional workflows have allowed.

Challenges Still Remain

The strategy appears coherent, but execution will not be without obstacles.

China remains a significant concern. Siemens Healthineers recently reduced its 2026 revenue outlook following ongoing market pressures in a country that historically represented about 10% of company revenue. Volume-based procurement initiatives continue to create challenges for foreign medtech companies, with Diagnostics feeling much of the impact.

Competition is also intensifying. Domestic Chinese players such as Mindray, Neusoft, and United Imaging continue gaining share in price-sensitive markets. Outside of China, Philips and GE HealthCare are running their own AI and ecosystem integration approaches.

Increasingly, competitive advantage is being defined by the ability to create durable data ecosystems rather than simply sell equipment.

Siemens Healthineers appears to recognize that the combination of robotics, AI, software, and imaging can help create a durable moat. In that environment, the pace of partnership formation may be just as important as the partnerships themselves.

Looking Ahead

If Siemens Healthineers continues emphasizing Imaging and Precision Therapy while reducing reliance on less-synergistic businesses, the result could be a company increasingly organized around neuro care.

The collection of partnerships announced over the past year suggests more than a series of isolated collaborations. Together, they resemble a platform strategy built around imaging, AI, robotics, and integrated clinical workflows. Whether that vision ultimately succeeds will depend on execution, but the direction appears increasingly clear.

For Siemens Healthineers, the future of neuroimaging may not be defined by any single partnership. It may be defined by how effectively the company combines all of them into a unified ecosystem before competitors can establish a similar position.